Abstract:BACKGROUND New oncology drug development has moved from general cytotoxic agents to molecular target-directed therapeutics. Consequently, there is a need to identify tumor types and individual patient tumors that express the target and could benefit from more selective therapies in clinical trials. Therefore, the in vivo models used in preclinical development should be\#8220;disease-oriented\#8221;and target-directed. Recently, we developed non-small cell lung cancer (NSCLC) xenograft models by transplanting human fresh tumor fragments into nude mice (HuPrimeTM), which have been used for test of cytotoxic and targeted anticancer agents. METHODS The fresh NSCLC tumor samples were collected from local hospitals. The tumor fragments of 1-2 mm were subcutaneously implanted in the flanks of the Balb/c nude mice. In the first passage, tumors derived from male patients were implanted into male mice, and tumors from women were inoculated into female mice. All therapeutic efficacy experiments used female mice. The test drugs included paclitaxel, gemcitabine, and the epidermal growth factor receptor (EGFR) inhibitor erlotinib. The EGFR and K-ras mutation status were investigated and compared with their efficacy results. RESULTS A total of 72 NSCLC samples were implanted into nude mice, and 13 HuPrimeTM tumor models were established with a tumor taking rates of 18% for the first passage. The tumor taking rates were higher in the second and third passages ranged from approximately 80-100%. The HuPrime tumor xenografts\#8217; architecture, the cell and histopathological morphology from the three generations mirrored in most of cases the original patient cancers. The mutations for EGFR and K-ras among the tested tumor samples were 56% and 22%, respectively. The two cytotoxic drugs paclitaxel and gemcitatbine produced tumor growth inhibition rates ranged from 50-53% regardless of the EGFR and K-ras mutation status. While erlotinib demonstrated a significant antitumor activity only in the tumors with EGFR mutation and wild-type K-ras, which were consistent with their clinical findings. CONCLUSIONS These results suggest that HuprimeTM tumor xenograft models provide a unique renewable source of tumor material for test of novel anticancer agents. They may predict more relevant clinical response rates and higher correlation with clinical findings than use of traditional xenograft models established from long-term cultured cancer cell lines. Especially, they have advantages for test of target-oriented therapeutics in new drugs development programs. Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr LB-65.

Personalized Primary Tumor Xenograft Model Established for the Pre-Clinical Trial to Guide Postoperative Chemotherapy

Personalized Cancer Therapy Using a Patient-Derived Tumor Tissue Xenograft Model: a Translational Field Worthy of Exploring Further?

Establishment of a PDTT xenograft model of gastric carcinoma and its application in personalized therapeutic regimen selection.

Assessment of a Novel VEGF Targeted Agent Using Patient-Derived Tumor Tissue Xenograft Models of Colon Carcinoma with Lymphatic and Hepatic Metastases

Establishing A Patient-Derived Colorectal Cancer Xenograft Model For Translational Research

Establishment of Patient-Derived Gastric Cancer Xenografts: a Useful Tool for Preclinical Evaluation of Targeted Therapies Involving Alterations in HER-2, MET and FGFR2 Signaling Pathways

A Multicenter Clinical Study: Personalized Medication for Advanced Gastrointestinal Carcinomas with the Guidance of Patient-Derived Tumor Xenograft (PDTX).

A Preliminary Study on the Establishment of the PDTX Model

Establishment and Identification of Patient-Derived Xenograft Model for Oral Squamous Cell Carcinoma

The Essential Factors of Establishing Patient-derived Tumor Model.

Patient-derived Human Tumour Tissue Xenografts in Immunodeficient Mice: a Systematic Review

Human tumor xenografts in mouse as a model for evaluating therapeutic efficacy of monoclonal antibodies or antibody-drug conjugate targeting receptor tyrosine kinases.

A preliminary discussion on establishment of patient-derived tumor xenograft (PDTX) model and testing of pharmacodynamics

Preclinical tumor organoid models in personalized cancer therapy: Not everyone fits the mold

Abstract #LB-65: Test of Cytotoxic and Targeted Anticancer Drugs Using Human Primary Non-Small Cell Lung Cancer Xenograft Models

Cancer Cell Membrane‐Coated Nanoparticles for Personalized Therapy in Patient‐Derived Xenograft Models

Patient-derived xenograft models for gastrointestinal tumors: A single-center retrospective study

Prediction of Cancer Patient Responses to Different Treatments Using Personalized Tumor Models or Models with Matching Genomic Profiles.

First-Generation Tumor Xenografts: A Link Between Patient-Derived Xenograft Models and Clinical Disease

100P Individualized Treatment of Advanced Digestive System Tumour Guided by PDTX Mouse Model: A Multicenter Trial